Key Financial Figures (Consolidated, ₹ lakhs)

H1 FY27 Performance:

  • Revenue from operations: ₹3,107.00 lakhs, up 39.42% YoY from ₹2,228.57 lakhs in H1 FY26
  • Other income: ₹18.07 lakhs, up 640.57% YoY from ₹2.44 lakhs
  • Total income: ₹3,125.07 lakhs, up 40.07% YoY from ₹2,231.01 lakhs
  • Total expenditure: ₹2,941.72 lakhs, up 53.60% YoY from ₹1,915.23 lakhs
  • EBITDA: ₹183.35 lakhs, down 41.94% YoY from ₹315.78 lakhs
  • EBITDA margin: 5.90%, down 810 bps from 14.00% in H1 FY26
  • Depreciation: ₹59.32 lakhs, up 162.25% YoY from ₹22.62 lakhs
  • Interest: ₹7.39 lakhs, down 80.86% YoY from ₹38.61 lakhs
  • Profit before tax: ₹116.63 lakhs, down 54.18% YoY from ₹254.56 lakhs
  • Tax: ₹44.86 lakhs, down 35.20% YoY from ₹69.23 lakhs
  • PAT: ₹71.77 lakhs, down 61.27% YoY from ₹185.33 lakhs
  • PAT margin: 2.30%, down 570 bps from 8.00% in H1 FY26
  • EPS: ₹0.52, down 61.48% YoY from ₹1.35

Comparative Performance:

  • H2 FY26 Revenue: ₹3,174.96 lakhs (H1 FY27 shows 2.14% decline sequentially)
  • FY26 Full Year Revenue: ₹5,403.53 lakhs
  • H2 FY26 PAT: ₹307.90 lakhs (H1 FY27 shows 76.69% decline sequentially)
  • FY26 Full Year PAT: ₹493.23 lakhs

Revenue Mix (H1 FY27):

  • Government business: 59.05%
  • Private business: 40.95%

Balance Sheet Position (₹ lakhs)

As at 30 September 2026:

  • Share capital: ₹1,375.39 lakhs (unchanged from 31 March 2026)
  • Reserves: ₹5,119.00 lakhs (increased from ₹5,059.13 lakhs at 31 March 2026)
  • Short-term borrowings: ₹122.32 lakhs (increased from ₹0.24 lakhs)
  • Trade payables: ₹279.21 lakhs (increased from ₹180.09 lakhs)
  • Other liabilities: ₹203.77 lakhs (decreased from ₹334.35 lakhs)
  • Total liabilities: ₹7,099.69 lakhs (increased from ₹6,949.20 lakhs)
  • Fixed assets: ₹947.26 lakhs (increased from ₹587.75 lakhs)
  • Other non-current assets: ₹641.63 lakhs (increased from ₹194.25 lakhs)
  • Trade receivables: ₹2,596.47 lakhs (increased from ₹2,106.90 lakhs)
  • Other current assets: ₹2,914.33 lakhs (decreased from ₹4,060.30 lakhs)
  • Total assets: ₹7,099.69 lakhs

Operational and Strategic Updates

Business Model Overview:

Earkart Limited operates as an integrated hearing healthcare platform spanning diagnostics, hearing aids, technology-enabled solutions and ENT pharmaceuticals. The company manufactures hearing aids under EQFY, Fame, Radius and Tiny brands at its Noida facility.

Shop-in-Shop (SIS) Clinic Network:

  • 105 SIS clinics operational across 55+ cities in 24 states
  • OMNI 2.0 remote audiometry technology enables one audiologist to serve 4-7 clinics remotely
  • Clinics offer hearing tests, hearing aid fitting, and ENT pharmaceutical formulations

Technology Development:

  • OMNI 2.0: Patented remote audiometry device (Indian patent granted October 2025)
  • Capabilities include video otoscopy, air and bone conduction audiometry, tympanometry, OAE including newborn screening
  • Can program Bluetooth-enabled and any programmable hearing aid of any brand in real time
  • Portable with 11-inch display, wireless connectivity, and 8-hour battery life

Manufacturing Facility:

  • Location: Noida, Uttar Pradesh
  • Size: 13,000 sq ft (expanded from 4,500 sq ft at IPO)
  • Installed capacity: 200,000 units per year with headroom for second shift
  • Certifications: ISO 13485:2016, CDSCO-approved, BIS compliant
  • Capabilities: End-to-end hearing aid production, in-house PCBA integration and testing

International Expansion:

  • U.S. FDA registration completed for four hearing aid categories: Prescription, OTC, Wireless Prescription, and Wireless OTC
  • Earkart Inc. (USA): Wholly-owned subsidiary for hearing-care distribution and services
  • Earkart Health Limited (UK): 65% owned subsidiary for hearing-care distribution and services
  • Current exports to Sri Lanka, Bangladesh, and Nepal

Subsidiary Structure:

  • Earkart Pharmaceuticals Pvt. Ltd. (India, 100% owned): Pharma business
  • 7 ENT pharmaceutical formulations launched: nasal sprays, tablets, capsules, and ear drops for nasal allergy, tinnitus, and earwax management

Government Business:

  • Strong presence on Government e-Marketplace (GeM) portal
  • Long-standing association with ALIMCO as a supplier
  • Multiple ALIMCO orders secured
  • Participation in government-led hearing healthcare programs

Recent Event Participation:

  • Participated in ISOCON 2026 held in Amritsar on 9-10 October 2026
  • Showcased hearing healthcare solutions, OMNI technology, and ENT pharmaceutical portfolio
  • Engagement led by Mr. Rahul Salesha (Director) and Ms. Monika Misra (Promoter & Whole-Time Director)

Shareholding Pattern (as at 30 September 2026):

  • Domestic institutions: 22.20%
  • Retail and others: 20.45%

Company Background

  • Incorporated: 2021
  • Listed on BSE SME
  • Conversion to public limited company: 2025
  • Leadership team with 25+ years of experience